Abstract
Dolutegravir suppresses this integration enzyme, so human immune virus can’t create every greater copies of itself, thus ‘’integrase inhibitor.’’ Dolutegravir is hastily absorbed pursuing oral administration. The median maximum plasma concentration is reached 1.5–2.5 hours after oral uptake with a mean half-life of 12–15 hours, rendering feasible for once-daily dosing without the need for pharmacological boosting. The terminal half-life is about 14 hours. The apparent oral clearance is about 1 liter/hour. Fifty three percent of the total oral dose of dolutegravir is excreted unchanged in the feces, thirty two percent through urine as glucuronide (eighteen percent) or alkylated product (three point five percent), and other organic conjugated products sequencing from phase II liver metabolisms. Dolutegravir’s categorized as pregnancy category B (no confirmation of pitfall in humans) means either animal-reproduction inquests have not substantiated a fetal peril but there are no restrained inquests in pregnant women or animal-reproduction inquests have reveal an adverse effect (distinctive than a de-escalate in fertility) that was not inveterate in restrained inquests in women in the first trimester (and there is no confirmation of a pitfall in later trimesters) or there is survey in animal that revealed the medication is safe in pregnant animal, but there is no fetal pitfall confirmation in pregnant women.Antiviral Pregnancy Registry (APR) revealed that as of January 2017, pregnancy outcomes and birth defects were analyzed from 142 pregnancies with reported exposure to DTG during pregnancy. There were 128 live births reported (3 terminations, 11 miscarriages, no stillbirths). Only 4 (3.0%) reported birth defects, which is similar to the expected rate of birth defects in the general population. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPIC) displayed that as of July 2017, 101 pregnancies with exposure to DTG had been identified with 84 birth outcomes. Rates of preterm delivery and “small for gestational age” were identical to outcomes reported from women on alternative regimens (standard of care in the United Kingdom of Great Britain and Northern Ireland).
Author Contributions
Copyright © 2022 Gudisa Bereda
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests
The author has no financial or proprietary interest in any of material discussed in this article.
Citation:
Introduction
Dolutegravir is a potent inhibitor of the HIV-1 integrase that has revealed best security, tolerability, predictable pharmacokinetics and efficacy in management naïve and proficiency adults in Phase III trials. DTG is currently FDA and EMA confirmed for both adults and adolescents twelve years and older, weighing ≥ forty kilogram, at a dose of 50 mg once a day depending in section on the data narrated herein 1, 2. When human immune virus infects a cell, it combines its viral genetic code into the human cell’s own code; this is called incorporation, using the integrase enzyme. Dolutegravir suppresses this integration enzyme, so human immune virus can’t create every greater copies of itself, thus ‘’integrase inhibitor.’’. DTG is the primary integrase strand transfer inhibitor that would be broadly used by people living with human immune virus (HIV) in the advancing world. DTG is a second2nd-ISTI frequently used as a constituent of preferred combined antiretroviral treatment (cART) 3, 4.
Mechanism of Action of Dolutegravir
Dolutegravir functions by interposing with an enzyme necessitated by HIV called integrase. Using Dolutegravir as section of combination therapy downgrades HIV’s capability to infect cells and create copies of itself. Dolutegravir is an INSTI that functions by suppressing the interjection of HIV deoxyribonucleic acid (DNA) into host cells, thereby obviating subsequent viral duplication. It fits loosely into the attaching pocket of the intasome and undergoes conformational revamps in the pocket structure while retaining its attaching capability 5.
Pharmacokinetics
Dolutegravir has favorable PK properties and remains PC well above the protein-adjusted 90% inhibitory accumulation for HIV-1 6.
Absorption
Dolutegravir is hastily absorbed pursuing per os administration. The median maximum plasma concentration is reached 1.5–2.5 hours after per os intake with a mean t1/2 of 12–15 hours, delivering reasonable for quotidian dosing without seek for pharmacological boosting. Bioavailability diversifies with lipid rich foods 7.
Distribution
Dolutegravir has got great attraction for plasma proteins, and .99% of dolutegravir is attached to plasma proteins, and it is depending of the plasma concentration. Dolutegravir has best discernment to distinctive body compartments and occurs to cross the BBB 8.
Metabolism
Dolutegravir is extendedly metabolized in the liver using the phase II metabolism initially through glucuronidation via uridine diphosphate glucuronosyltransferase (UGT) 1A1, while a least pathway (in Phase I) encloses cytochrome P (CYP450) 3A4 with other minor pathways (phase II) enclosing UGT1A3 and glucuronosyltransferase (GT) 1A9 9.
Elimination
The ultimate t1/2 is around 14 hours. The apparent oral clearance is near to 1 liter/hour. 53% of the daily dose of dolutegravir is excreted unchanged in the feces, thirty two percent through urine as glucuronide (eighteen percent) or alkylated product (three point five percent), and disparate organic conjugated products sequencing from phase II liver metabolisms. Around 1% of unchanged dolutegravir is excreted through urine, delivering it comparatively secure to use in mild or moderate renal problems 9.
Pregnancy
DTG security in pregnant women is not understood. Thereupon, the manufacturer recommends that dolutegravir should solely be used in pregnancy if “the implicit merit justifies the potential peril.” 10. Dolutegravir’s categorized as pregnancy category B (no confirmation of pitfall in humans) means either animal-reproduction inquests have not substantiated a fetal peril but there are no restrained inquests in pregnant women or animal-reproduction inquests have reveal a side effect (distinctive than a de-escalate in fertility) that was not inveterate in restrained inquests in women in the 1st trimester (and there is no confirmation of a pitfall in later trimesters) or there is survey in animal that revealed the medication is safe in pregnant animal, but there is no fetal pitfall confirmation in pregnant women 11.Information on DTG safety in women who started ART before pregnancy is limited and further studies are still needed, and some study written up beneath revealed: Tsepamo Study (Botswana) displayed that since August 2014 the Tsepamo Study has performed ongoing birth surveillance to evaluate the safety of ART in pregnancy. Recent analysis compared women who started either TDF/FTC/EFV (4593 rendered from August 2014 to August 2016) or TDF/FTC + DTG (845 delivered from November 2016 to April 2017) during pregnancy. The analysis found no significant differences in: total and severe adverse birth outcomes, preterm, very preterm birth, small for gestational age, very small for gestational age, stillbirth, and neonatal death. Adjusted risk ratios (aRR) for DTG-based regimens with EFV-based regimens as reference were respectively (for the above outcomes): aRR 1.0 (95% CI: 0.9–1.1); aRR 1.0 (95% CI: 0.8–1.2); aRR 1.0 (95% CI: 0.8–1.1); aRR 1.2 (95% CI: 0.8–1.7); aRR 1.0 (95% CI: 0.9–1.2); aRR 0.9 (95% CI: 0.7–1.2); aRR 0.9 (95% CI: 0.6–1.5); and aRR 1.0 (95% CI: 0.5– 1.9). Information on pregnancy safety in women with preconception exposure to DTG is still limited 12. Antiviral Pregnancy Registry (APR) revealed that as of January 2017, pregnancy outcomes and birth defects were analyzed from 142 pregnancies with reported exposure to DTG during pregnancy. There were 128 live births reported (3 terminations, 11 miscarriages, no stillbirths). Only 4 (3.0%) reported birth defects, which is similar to the expected rate of birth defects in the general population 13. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPIC) displayed that as of July 2017, 101 pregnancies with exposure to DTG had been identified with 84 birth outcomes. Rates of preterm delivery and “small for gestational age” were identical to outcomes reported from women on alternative regimens (standard of care in the United Kingdom of Great Britain and Northern Ireland) 14. In July 2019, WHO declared that dolutegravir is secure for women of child-bearing age. Therefore, TLD is currently the preferred 1st-line and second-line standard for entire populations, involving pregnant women and those of childbearing age 15, 16.
Conclusion
Dolutegravir has got great attraction for plasma proteins, and .99% of dolutegravir is attached to plasma proteins, and it is depending of the plasma concentration. Dolutegravir has good penetration to distinctive body compartments and appears to cross the blood–brain barrier. Antiviral Pregnancy Registry (APR) revealed that as of January 2017, pregnancy outcomes and birth defects were analyzed from 142 pregnancies with reported exposure to DTG during pregnancy. There were 128 live births reported (3 terminations, 11 miscarriages, no stillbirths). Only 4 (3.0%) reported birth defects, which is similar to the expected rate of birth defects in the general population.Antiviral Pregnancy Registry (APR) revealed that as of January 2017, pregnancy outcomes and birth defects were analyzed from 142 pregnancies with reported exposure to DTG during pregnancy. There were 128 live births reported (3 terminations, 11 miscarriages, no stillbirths). Only 4 (3.0%) reported birth defects, which is similar to the expected rate of birth defects in the general population. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPIC) displayed that as of July 2017, 101 pregnancies with exposure to DTG had been identified with 84 birth outcomes. Rates of preterm delivery and “small for gestational age” were identical to outcomes reported from women on alternative regimens (standard of care in the United Kingdom of Great Britain and Northern Ireland).
Acknowledgments
The author would be grateful to anonymous reviewers by the comments that increase the quality of this manuscript.
Data Sources
Sources searched include Google Scholar, Research Gate, PubMed, NCBI, NDSS, PMID, PMCID, Scopus database, Scielo and Cochrane database. Search terms included: pharmacokinetics and pregnancy profile of dolutegravir
Funding
None
Availability of Data and Materials
The datasets generated during the current study are available with correspondent author.
Abbreviations
References
- 1.Viani R M. (2015) Pharmacokinetics and Efficacy of Dolutegravir. in Treatment-Experienced HIV-1 Infected Adolescents: 48-Week Results from IMPAACT P1093. Pediatr Infect Dis 34(11), 1207-1213.
- 2.Raffi F, Jaeger H, Quiros-Roldan E. (2013) Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 13, 927-935.
- 3.Mbhele N, Chimukangara B, Gordon M. (2021) HIV-1 integrase strand transfer inhibitors: A review of current drugs, recent advances and drug resistance. International journal of antimicrobial agents. 106343.
- 4.Seatla K K, Maruapula D, Choga W T, Ntsipe T, Mathiba N et al. (2021) HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana. , Viruses 13(4), 594.
- 5.Scévola S, Tiraboschi J M, Podzamczer D. (2020) Nothing is perfect: the safety issues of integrase inhibitor regimens. Expert opinion on drug safety. 19(6), 683-94.
- 6.Adams J L, Patterson K B, Prince H M.Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. , Antivir Ther 18(8), 1005-1013.
- 7.Song I, Borland J, Chen S. (2012) Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 56(3), 1627-1629.
- 8.Cottrell M L, Hadzic T, Kashuba A D. (2013) Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. , Clin Pharmacokinet 52(11), 981-994.
- 9.Castellino S, Moss L, Wagner D. (2013) Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 57(8), 3536-3546.
- 10.Reis W, Gaio J, Chau T, Ramos F, Reis C. (2020) Antivirals 11. Pharmacology in Clinical Neurosciences. 499.
- 11.Caniglia E C, Shapiro R, Diseko M, Wylie B J, Zera C et al. (2020) Weight gain during pregnancy among women initiating dolutegravir in Botswana. , EClinicalMedicine 29, 100615.
- 12.Zash R. (2017) Dolutegravir/tenofovir/emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe as efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC) in nationwide birth outcomes surveillance in Botswana. IAS. 23-26.
- 13.Vannappagari V. (2017) Dolutegravir use during pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry (APR). IAS. Poster abstract MOPEBO283 , Paris 23-26.